Amylyx 2025 Q3 Earnings 52.7% Net Loss Reduction and Extended Cash Runway to 2028

Amylyx (AMLX) reported Q3 2025 results that exceeded Wall Street’s earnings expectations while narrowing losses by 52.7% year-over-year. , extending its cash runway to 2028, and provided updated guidance for the LUCIDITY trial, with recruitment now expected to conclude in Q1 2026.

Revenue

The total revenue of Amylyx decreased by 100.0% to $0 in 2025 Q3, down from $416,000 in 2024 Q3.

Earnings/Net Income

. Meanwhile, , . The EPS improvement and 52.7% net loss reduction highlight the company’s progress in cost control and financial efficiency.

Price Action

The stock price of Amylyx has dropped 4.01% during the latest trading day, , and has dropped 7.64% month-to-date.

Post-Earnings Price Action Review

Amylyx’s shares have experienced heightened volatility following the earnings release, , reflecting mixed investor sentiment. , . .

CEO Commentary

, Co-CEOs of Amylyx, emphasized progress toward 2026 milestones, . , . The Co-CEOs expressed optimism about advancing avexitide’s development, . , .

Guidance

, , . , . , , . .

Additional News

Amylyx Pharmaceuticals, Inc. , . , . Separately, , .